Reduced Apela/APJ system expression in patients with pulmonary artery hypertension secondary to chronic obstructive pulmonary disease

Bisserier, 2020, Current and emerging therapeutic approaches to pulmonary hypertension, Rev Cardiovasc Med, 21, 163, 10.31083/j.rcm.2020.02.597 Rabe, 2017, Chronic obstructive pulmonary disease, Lancet., 389, 1931, 10.1016/S0140-6736(17)31222-9 Andersen, 2012, Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease, J HeartLung Transplant, 31, 373, 10.1016/j.healun.2011.11.020 Chaouat, 2005, Severe pulmonary hypertension and chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 172, 189, 10.1164/rccm.200401-006OC Zhou, 2019, Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 394, 1145, 10.1016/S0140-6736(19)30427-1 Wang, 2019, Apela Promotes Cardiomyocyte Differentiation from Transgenic Human Embryonic Stem Cell Lines, Appl Biochem Biotechnol, 189, 396, 10.1007/s12010-019-03012-2 Xu, 2018, Biological functions of Elabela, a novel endogenous ligand of APJ receptor, J Cell Physiol, 233, 6472, 10.1002/jcp.26492 Pan, 2020, Apela improves cardiac and renal function in mice with acute myocardial infarction, J Cell Mol Med, 24, 10382, 10.1111/jcmm.15651 Jin, 2021, Elabela gene therapy promotes angiogenesis after myocardial infarction, J Cell Mol Med, 25, 8537, 10.1111/jcmm.16814 Hu, 2022, Apela gene therapy alleviates pulmonary hypertension in rats, FASEB J, 36, e22431, 10.1096/fj.202200266R Vogelmeier, 2017, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary, Am J Respir Crit Care Med., 195, 557, 10.1164/rccm.201701-0218PP Rudski, 2010, J Am Soc Echocardiogr, 23, 685, 10.1016/j.echo.2010.05.010 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262 Zhou, 2020, Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases, J Cardiovasc Pharmacol, 75, 284, 10.1097/FJC.0000000000000803 O'Dowd, 1993, A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11, Gene, 136, 355, 10.1016/0378-1119(93)90495-O Tatemoto, 1998, Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem Biophys Res Commun, 251, 471, 10.1006/bbrc.1998.9489 Chng, 2013, ELABELA: a hormone essential for heart development signals via the apelin receptor, Dev Cell, 27, 672, 10.1016/j.devcel.2013.11.002 Pauli, 2014, Toddler: an embryonic signal that promotes cell movement via Apelin receptors, Science, 343, 10.1126/science.1248636 Shin, 2017, Apelinergic System Structure and Function, Compr Physiol, 8, 407, 10.1002/cphy.c170028 Marsault, 2019, The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders, Ann N Y Acad Sci, 1455, 12, 10.1111/nyas.14123 Yang, 2017, Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension, Circulation., 135, 1160, 10.1161/CIRCULATIONAHA.116.023218 Wang, 2015, Elabela-apelin receptor signaling pathway is functional in mammalian systems, Sci Rep, 5, 8170, 10.1038/srep08170 Evans, 2021, Endothelial cells in the pathogenesis of pulmonary arterial hypertension, Eur Respir J, 58, 10.1183/13993003.03957-2020 Frid, 2002, Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis, Circ Res, 90, 1189, 10.1161/01.RES.0000021432.70309.28 Rabinovitch, 2014, Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension, Circ Res, 115, 165, 10.1161/CIRCRESAHA.113.301141 Rai, 2008, The cancer paradigm of severe pulmonary arterial hypertension[J], Am J Respir Crit Care Med, 178, 558, 10.1164/rccm.200709-1369PP Masri, 2007, Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension, Am J Physiol Lung Cell Mol Physiol, 293, L548, 10.1152/ajplung.00428.2006 Good, 2015, Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension, Am J Pathol, 185, 1850, 10.1016/j.ajpath.2015.03.019 Sitbon, 2012, Pathways in pulmonary arterial hypertension: the future is here, Eur Respir Rev, 21, 321, 10.1183/09059180.00004812 Vanhoutte, 2016, Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator, Circ Res, 119, 375, 10.1161/CIRCRESAHA.116.306531 Kim, 2014, Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension, Mol Cells, 37, 196, 10.14348/molcells.2014.2308 Alastalo, 2011, Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival, J Clin Invest, 121, 3735, 10.1172/JCI43382 Brash, 2018, Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension, JACC Basic Transl Sci, 3, 176, 10.1016/j.jacbts.2018.01.013